- Home
- CAVA vs RPRX Comparison
CAVA vs RPRX Comparison
Compare CAVA & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAVA
- RPRX
- Stock Information
- Founded
- CAVA 2006
- RPRX 1996
- Country
- CAVA United States
- RPRX United States
- Employees
- CAVA N/A
- RPRX N/A
- Industry
- CAVA Restaurants
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- CAVA Consumer Discretionary
- RPRX Health Care
- Exchange
- CAVA Nasdaq
- RPRX Nasdaq
- Market Cap
- CAVA 9.9B
- RPRX 14.2B
- IPO Year
- CAVA 2023
- RPRX 2020
- Fundamental
- Price
- CAVA $86.00
- RPRX $32.60
- Analyst Decision
- CAVA Buy
- RPRX Strong Buy
- Analyst Count
- CAVA 14
- RPRX 4
- Target Price
- CAVA $124.71
- RPRX $42.50
- AVG Volume (30 Days)
- CAVA 4.2M
- RPRX 5.5M
- Earning Date
- CAVA 05-27-2025
- RPRX 05-08-2025
- Dividend Yield
- CAVA N/A
- RPRX 2.71%
- EPS Growth
- CAVA 423.81
- RPRX N/A
- EPS
- CAVA 1.10
- RPRX 1.91
- Revenue
- CAVA $963,713,000.00
- RPRX $2,263,576,000.00
- Revenue This Year
- CAVA $25.56
- RPRX $31.56
- Revenue Next Year
- CAVA $21.07
- RPRX $5.94
- P/E Ratio
- CAVA $78.18
- RPRX $17.05
- Revenue Growth
- CAVA 32.25
- RPRX N/A
- 52 Week Low
- CAVA $58.22
- RPRX $24.05
- 52 Week High
- CAVA $172.43
- RPRX $34.20
- Technical
- Relative Strength Index (RSI)
- CAVA 47.43
- RPRX 54.58
- Support Level
- CAVA $83.35
- RPRX $32.02
- Resistance Level
- CAVA $93.25
- RPRX $32.31
- Average True Range (ATR)
- CAVA 6.50
- RPRX 0.97
- MACD
- CAVA 1.08
- RPRX 0.12
- Stochastic Oscillator
- CAVA 68.35
- RPRX 97.84
About CAVA CAVA Group Inc.
Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates all of its revenue from the CAVA segment.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.